■尽管结膜炎是COVID-19感染最常见的眼部表现,据报道,威胁视力的视网膜受累。在这里,我们通过多模式视网膜成像报告并描述了5例急性视力丧失,这些急性视力丧失继发于假定的脉络膜视网膜血管病变,这些病变与严重程度不同的COVID-19感染相关,视觉发病率,和治疗反应,并回顾有关COVID-19感染与视网膜微血管变化之间关联的现有文献。
■观察性案例系列和文献综述。
■多中心病例系列5例患者就诊于学术中心和私人办公室,暂时与COVID-19感染相关的急性视力丧失。使用在线数据库对文献进行了综述。
■5例患者的10只眼,3男2女,平均年龄30.8岁(中位数33岁,范围16~44岁).所有患者最近都有一次COVID-19发作,症状从轻度感染到危及生命的脑病。治疗他们的视网膜疾病包括局部治疗,口服,玻璃体内,静脉注射类固醇,保留类固醇的免疫抑制,视网膜光凝,抗病毒药物,抗血小板和抗凝剂.治疗反应和视力恢复范围从基线视力完全恢复到永久性视力丧失和需要慢性免疫抑制。
临床医生应注意COVID-19感染后可能威胁视力的视网膜受累。如果找到,应考虑抗炎治疗和抗凝治疗,除了密切监测,因为一些患有这种疾病的患者可能需要慢性免疫抑制和/或抗VEGF治疗。
UNASSIGNED: Although conjunctivitis represents the most common ocular manifestation of COVID-19 infection, sight-threatening retinal involvement has been reported. Herein, we report and characterize with multimodal retinal imaging 5 cases of acute vision loss secondary to presumed chorioretinal vasculopathy temporally associated with COVID-19 infection with varying severity, visual morbidity, and treatment response, and review the available literature on the association between COVID-19 infection and retinal microvascular changes.
UNASSIGNED: Observational case series and literature review.
UNASSIGNED: Multicenter case series of 5 patients who presented to academic centers and private offices with acute vision loss temporally associated with COVID-19 infection. A review of the literature was conducted using online databases.
UNASSIGNED: 10 eyes of 5 patients, 3 men and 2 women, with a mean age of 30.8 years (median 33, range 16-44) were described. All patients had a recently preceding episode of COVID-19, with symptomatology ranging from mild infection to life-threatening encephalopathy. Treatment for their retinal disease included topical, oral, intravitreal, and intravenous steroids, steroid-sparing immunosuppression, retinal photocoagulation, antivirals, and antiplatelet and anticoagulant agents. Treatment response and visual recovery ranged from complete recovery of baseline acuity to permanent vision loss and need for chronic immunosuppression.
UNASSIGNED: Clinicians should be mindful of the potential for vision-threatening retinal involvement after COVID-19 infection. If found, treatment with both anti-inflammatory therapy and anticoagulation should be considered, in addition to close monitoring, as some patients with this spectrum of disease may require chronic immune suppression and/or anti-VEGF therapy.